UBS downgraded Ambev (ABEV) to Sell from Neutral with a $2.65 price target The firm believes the stock’s risk/reward at current levels is “skewed to the downside” following the 32% rally over the past six months. There is a “growing disconnect” between Ambev’s earnings growth profile, Brazil’s cost of capital, and valuation, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEV:
- Ambev Discloses March 2026 Insider Equity Transactions Under Brazilian CVM Rules
- Ambev Reports March 2026 Treasury Share Transactions and Purchases
- Ambev Updates Fiscal Council Slate and Refiles AGM Voting Materials After Minority Shareholder Change
- Ambev Board Sets 2025 Profit Allocation, 2026 Pay Limits and Approves New Share Issue
- Ambev Board Sets Profit Allocation, Governance Changes and Capital Increase Ahead of April 30 Meetings